Dose Range Study of CD5789 in Acne Vulgaris

Summary

To assess the efficacy and safety of different concentrations of CD5789 cream in participants with acne vulgaris for the purpose of dose identification.

Timeline

Start

2012-06-20

Primary completion

2013-07-24

Completion

2014-06-12

Outcome

Mixed primary results

registry analysis (superiority test); CD5789 50 mcg/g Cream vs CD5789 Vehicle Cream; p = 0.040; Percentage difference 16.393 (95% CI -0.249 to 33.036) NCT01616654 ↗

registry analysis (superiority test); CD5789 25 mcg/g Cream vs Vehicle Cream; p = 0.108; Percentage difference -6.74 (95% CI -14.96 to 1.48) NCT01616654 ↗

registry analysis (superiority test); CD5789 100 mcg/g Cream vs CD5789 Vehicle Cream; p = 0.038; Cochran-Mantel-Haenszel NCT01616654 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Tazarotene	Small molecule	0.1 %	Topical
Subject	Trifarotene	Small molecule	25 unknown	Topical
Subject	Trifarotene	Small molecule	50 unknown	Topical
Subject	Trifarotene	Small molecule	100 unknown	Topical

Indications